Charles Dumontet
Affiliations: | 1993-1995 | Cancer Research Center of Lyon, Lyon | Université Lyon 1, Université de Lyon |
Google:
"Charles Dumontet"Mean distance: 20.07 (cluster 32)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Decaup E, Rossi C, Gravelle P, et al. (2019) A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma. Frontiers in Immunology. 10: 1943 |
| Guillon R, Rahimova R, Preeti, et al. (2019) Lead optimization and biological evaluation of fragment-based cN-II inhibitors. European Journal of Medicinal Chemistry. 168: 28-44 |
| Alameh G, Emptoz-Bonneton A, Rolland de Ravel M, et al. (2019) In vitro modulation of multidrug resistance by pregnane steroids and in vivo inhibition of tumour development by 7α-OBz-11α(R)-OTHP-5β-pregnanedione in K562/R7 and H295R cell xenografts. Journal of Enzyme Inhibition and Medicinal Chemistry. 34: 684-691 |
| Boyle EM, Davies FE, Deshpande S, et al. (2019) Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Myeloma Blood. 134: 4333-4333 |
| Jordheim LP, Chettab K, Cros-Perrial E, et al. (2018) Unexpected Growth-Promoting Effect of Oxaliplatin in Excision Repair Cross-Complementation Group 1 Transfected Human Colon Cancer Cells. Pharmacology. 102: 161-168 |
| Wei X, Calvo-Vidal MN, Chen S, et al. (2018) Germline mutations in lysine specific demethylase 1 (LSD1/KDM1A) confer susceptibility to multiple myeloma. Cancer Research |
| Boyle EM, Rosenthal A, Wang Y, et al. (2018) Global Expression Changes of Malignant Plasma Cells over Time Reveals the Evolutionary Development of Signatures of Aggressive Clinical Behavior Blood. 132: 4457-4457 |
| Boyle EM, Ashby C, Tytarenko RG, et al. (2018) Mutations and Copy Number Changes Predict Progression from Smoldering Myeloma to Symptomatic Myeloma in the Era of Novel IMWG Criteria Blood. 132: 4456-4456 |
| Barret JM, Meseure D, Bataillon G, et al. (2018) Abstract 774: Anti-Müllerian hormone type II receptor (AMHRII) found expressed in human non-gynecological solid tumors, suggesting potential broader applications for anti-AMHRII-based therapy Cancer Research. 78: 774-774 |
| Cadassou O, Raza MZ, Cros-Perrial E, et al. (2018) Abstract 3164: Impact of cN-II and CD73 inhibition on cancer cell migration Tumor Biology |